Android Apple

New Amgen Drug MariTide Shows Promising Weight Loss in Early Data

By The New York Times   |   3 weeks ago
New Amgen Drug MariTide Shows Promising Weight Loss in Early Data

Amgen's experimental obesity drug, MariTide, showed promising results in a Phase 2 trial, with patients experiencing up to 20% weight loss in a year. The drug, delivered monthly via injection, differs from existing treatments and could offer a new approach to obesity management.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.